MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH Purchases Shares of 66,252 The Clorox Company (NYSE:CLX)

MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH acquired a new position in shares of The Clorox Company (NYSE:CLX - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 66,252 shares of the company's stock, valued at approximately $9,756,000. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH owned 0.05% of Clorox at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the business. Norges Bank bought a new position in shares of Clorox during the fourth quarter worth approximately $259,041,000. FMR LLC grew its position in Clorox by 75.4% during the fourth quarter. FMR LLC now owns 1,361,758 shares of the company's stock worth $221,163,000 after buying an additional 585,526 shares in the last quarter. Marshall Wace LLP increased its stake in Clorox by 549.8% during the 4th quarter. Marshall Wace LLP now owns 542,726 shares of the company's stock worth $88,144,000 after acquiring an additional 459,203 shares during the period. ExodusPoint Capital Management LP raised its holdings in Clorox by 187.9% in the 4th quarter. ExodusPoint Capital Management LP now owns 698,900 shares of the company's stock valued at $113,508,000 after acquiring an additional 456,114 shares in the last quarter. Finally, Man Group plc lifted its position in shares of Clorox by 154.6% during the 4th quarter. Man Group plc now owns 570,503 shares of the company's stock valued at $92,655,000 after acquiring an additional 346,449 shares during the period. 78.53% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently commented on CLX. UBS Group decreased their price target on Clorox from $176.00 to $154.00 and set a "neutral" rating on the stock in a research report on Thursday, April 17th. Citigroup dropped their target price on shares of Clorox from $165.00 to $150.00 and set a "neutral" rating for the company in a research report on Monday, April 14th. JPMorgan Chase & Co. reduced their price target on shares of Clorox from $151.00 to $144.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 6th. Morgan Stanley decreased their price objective on shares of Clorox from $165.00 to $150.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Finally, Wells Fargo & Company cut their target price on Clorox from $145.00 to $142.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $151.23.

Insider Transactions at Clorox

In related news, Director Pierre R. Breber acquired 4,000 shares of the stock in a transaction dated Wednesday, May 7th. The stock was bought at an average cost of $136.57 per share, for a total transaction of $546,280.00. Following the completion of the transaction, the director now directly owns 4,000 shares of the company's stock, valued at $546,280. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.57% of the stock is owned by company insiders.

Clorox Price Performance

CLX traded down $1.33 on Wednesday, reaching $120.77. The stock had a trading volume of 1,722,654 shares, compared to its average volume of 1,362,961. The company has a current ratio of 0.74, a quick ratio of 0.44 and a debt-to-equity ratio of 13.07. The company has a market capitalization of $14.88 billion, a price-to-earnings ratio of 21.68, a price-to-earnings-growth ratio of 2.80 and a beta of 0.54. The Clorox Company has a fifty-two week low of $120.71 and a fifty-two week high of $171.37. The firm has a 50-day moving average of $134.30 and a 200-day moving average of $147.74.

Clorox (NYSE:CLX - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.12). Clorox had a net margin of 9.89% and a return on equity of 324.23%. The firm had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.74 billion. During the same period in the prior year, the company earned $1.71 EPS. The business's quarterly revenue was down 8.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that The Clorox Company will post 7.15 EPS for the current year.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.